Pilot Study of Topical Imipramine Cream to Reduce UVB-Induced Microvesicle Particle Release and Skin Redness in Adults with Photosensitivity

What this Trial Is About

Researchers are studying individuals who have unusual reactions to sunlight, known as photosensitivity, to understand how ultraviolet B UVB light affects tiny particles called microvesicle particles MVP released from the skin. The study aims to find out if UVB exposure increases MVP levels, whether applying a topical medicine called imipramine can block this release, and if the cream can reduce skin redness caused by UVB. This is a Phase 1 pilot study sponsored by Wright State University focused on these responses in photosensitive adults. Participants will receive different treatments on UVB-exposed skin areas of the volar forearm and back. One area will be treated with 2 grams of 4% imipramine cream, another with 2 grams of a base cream without active medicine, and a third UVB-exposed area on the back will not receive any cream. These treatments are designed to compare the effects of imipramine against no treatment and the base cream. During the study, researchers will measure changes in microvesicle particle levels and skin redness at several times 4 hours after treatment for MVP levels and skin erythema, and also 24 hours after topical imipramine application for skin redness. Participants will provide their medical history and medication list and will be monitored for skin reactions. The total participation time covers these assessments following UVB exposure and cream application.

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects